Press Releases / Stock Exchange Intimation
| Date | Title | Report |
|---|
| 17 Jan 2020 | SPSL Intimation to SE Tribunal Meeting |  |
PDF 7.86 MB |
| 16 Jan 2020 | USFDA approval for Loratadine OTC Softgel Capsules | |
PDF 178 KB |
| 08 Jan 2020 | Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides | |
PDF 212 KB |
| 08 Jan 2020 | Press Release on appointment of new CEO & MD | |
PDF 251 KB |
| 08 Jan 2020 | SE Intimation on appointment of new CEO & MD | |
PDF 63 KB |
| 08 Jan 2020 | SE Intimation on KMP | |
PDF 83 KB |
| Date | Title | Report |
|---|
| 11 Dec 2019 | Intimation on Appointment of ID | |
PDF 64 KB |
| 05 Dec 2019 | Intimation of Investor/ Analyst Day | |
PDF 147 KB |
| 04 Dec 2019 | USFDA tentative approval for Diclofenac Potassium Softgel Capsules | |
PDF 406 KB |
| 25 Nov 2019 | Outcome of Postal Ballot – CG to Stelis | |
PDF 1.06 MB |
| 22 Nov 2019 | Disclosure of Related Party Transactions for the half year ended September 30, 2019 | |
PDF 227 KB |
| 08 Nov 2019 | Strides announces relaunch of Ranitidine tablets (Rx) for the US Market | |
PDF 402 KB |
| 06 Nov 2019 | Intimation SE Merger of WoS | |
PDF 1.67 MB |
| 04 Nov 2019 | Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits | |
PDF 181 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19 - Allotment of shares | |
PDF 421 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19_Grant of Options | |
PDF 50 KB |
| 25 Oct 2019 | Outcome of Board Meeting of Oct 25, 19 - Unaudited results | |
PDF 3.01 MB |
| 25 Oct 2019 | SPSL Earnings Call Intimation | |
PDF 176 KB |
| 23 Oct 2019 | TGA, Australia announces Ranitidine test results | |
PDF 421 KB |
| 23 Oct 2019 | EIR from USFDA on continued GMP status for formulation facility at Alathur | |
PDF 146 KB |
| 22 Oct 2019 | SE Intimation of Postal Ballot and Evoting | |
PDF 870 KB |
| 18 Oct 2019 | Intimation of Board Meeting for quarter ended Sep 2019 | |
PDF 92.9 KB |
| 04 Oct 2019 | Update on Encumbrance by Promoters | |
PDF 1.98 MB |
| 30 Sep 2019 | Shareholding pattern for the quarter ended 30 September 2019 | |
PDF 304 KB |
| 27 Sep 2019 | Strides receives USFDA approval for Solifenacin Succinate Tablets | |
PDF 304 KB |
| 27 Sep 2019 | Further Updates on Ranitidine Tablets for the US Markets | |
PDF 146 KB |
| 25 Sep 2019 | Update on Ranitidine tablets | |
PDF 224 KB |
| 20 Sep 2019 | Strides Board approves incremental investments in Stelis | |
PDF 316 KB |
| 20 Sep 2019 | Strides Board approves incremental investments in Stelis | |
PDF 227 KB |
| 20 Sep 2019 | Grant of Options under Strides Employee Stock Option Plan 2016 | |
PDF 52 KB |
| 11 Sep 2019 | Strides acquires strategic stake in Fairmed Healthcare AG in Europe | |
PDF 320 KB |
| 27 Aug 2019 | Strides acquires USFDA approved manufacturing facility in the US | |
PDF 349 KB |
| 09 Aug 2019 | Successful completion of US FDA inspection at its Alathur facility with "Zero 483 observations" | |
PDF 1.4 MB |
| 08 Aug 2019 | Intimation of Newspaper Advertisment - Interim Divided | |
PDF 144 KB |
| 31 Jul 2019 | Intimation on proceeding of 28th AGM – July 30, 2019 | |
PDF 174 KB |
| 31 Jul 2019 | Outcome of 28th AGM – July 30, 2019 | |
PDF 1.64 MB |
| 31 Jul 2019 | Update | |
PDF 125 KB |
| 29 Jul 2019 | Strides Outcome of the BM | |
PDF 3.19 MB |
| 29 Jul 2019 | SE Intimation Grant of Options | |
PDF 55 KB |
| 29 Jul 2019 | Strides Outcome of the BM - Dividend | |
PDF 57 KB |
| 29 Jul 2019 | SPSL 2019 Merger-Intimation to SE | |
PDF 175 KB |
| 29 Jul 2019 | Strides JVin Hong Kong | |
PDF 158 KB |
| 29 Jul 2019 | Strides Board Meeting Outcome | |
PDF 3.18 MB |
| 29 Jul 2019 | Strides Outcome of the BM Interim Dividend | |
PDF 57 KB |
| 29 Jul 2019 | SPSL Earnings Call Intimation | |
PDF 175 KB |
| 26 Jul 2019 | Intimation of Newspaper Advertisment - Q1 Meeting FY 20 | |
PDF 868 KB |
| 23 Jul 2019 | Intimation of Board Meeting for Q1 FY 2020 | |
PDF 94 KB |
| 23 Jul 2019 | EIR from USFDA on continued GMP status for the flagship facility in Bangalore | |
PDF 132 KB |
| 20 Jul 2019 | Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore | |
PDF 217 KB |
| 17 Jul 2019 | Clarification on the Article appeared in Economic Times on July 17, 2019 | |
PDF 333 KB |
| 10 Jul 2019 | Update on “Strides announces final closure of Arrow transaction" | |
PDF 133 KB |
| 08 Jul 2019 | SE Intimation - newspaper advertisment on AGM | |
PDF 538 KB |
| 05 Jul 2019 | SE Intimation - Book closure intimation and Record date | |
PDF 49 KB |
| 05 Jul 2019 | SE Intimation - AGM Notice and Annual Report for FY 18-19 | |
PDF 4.13 MB |
| 02 Jul 2019 | Update relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”. | |
PDF 129 KB |
| 01 Jul 2019 | Update on “Strides to exit its investment in Arrow for AUD 394 Million" | |
PDF 128 KB |
| 30 Jun 2019 | Shareholding pattern for the quarter ended 30 june 2019 | |
PDF 186 KB |
| 08 Jun 2019 | Disclosure of Related Party Transactions for the half year ended March 31, 2019 | |
PDF 285 KB |
| 05 Jun 2019 | Notice for transferring of equity shares to Investor Education and Protection Fund (IEPF) | |
PDF 427 KB |
| 21 May 2019 | Annual Secretarial Compliance Report for the year ended March 31, 2019 | |
PDF 1.26 MB |
| 10 May 2019 | Audited Financial Results | |
PDF 2.2 MB |
| 10 May 2019 | Declaration of Final Dividend | |
PDF 117 KB |
| 10 May 2019 | SPSL Earnings Call Intimation | |
PDF 175 KB |
| 06 May 2019 | USFDA classifies Strides Puducherry facility as Official Action Initiated (OAI) | |
PDF 146 KB |
| 04 May 2019 | Board Meeting for Consideration of Audited Financial Results for the quarter and year ended March 31, 2019 | |
PDF 89 KB |
| 03 May 2019 | Vivimed Life Sciences Private Limited (VLSPL) issues voluntary recall of 19 lots of Losartan Pottasium Tablets in USA due to detection of trace amount of N-Nitriso-N-methyl-4-aminobutyric acid (NMBA) impurity. These lots were manufactured at VLSPL's Alathur facility prior to acquisition by Strides | |
PDF 535 KB |
| 04 Apr 2019 | Strides pharma intimation on window closure | |
PDF 89 KB |
| 02 Apr 2019 | Receipt of Establishment Inspection Report (EIR) from US FDA for Singapore facility | |
PDF 997 KB |
| 02 Apr 2019 | Strides to launch Potassium Chloride Extended-Release Tablets in the US market | |
PDF 997 KB |
| 01 Apr 2019 | Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information | |
PDF 350 KB |
| 31 Mar 2019 | Strides Shareholding pattern | |
PDF 4 MB |
| 27 Mar 2019 | USFDA approval for its greenfield oral dosage facility in Singapore | |
PDF 170 KB |
| 20 Feb 2019 | USFDA approval for Ethosuximide Softgel Capsules | |
PDF 187 KB |
| 13 Feb 2019 | USFDA approval for Triamcinolone Acetonide Cream | |
PDF 181 KB |
| 06 Feb 2019 | EIR from USFDA on continued GMP status for the flagship facility in Bangalore | |
PDF 177 KB |
| 29 Jan 2019 | Outcome of Board meeting | |
PDF 2.03 MB |
| 29 Jan 2019 | Strides to exit its investment in Arrow | |
PDF 328 KB |
| 29 Jan 2019 | Strides to acquire 80% stake in Pharmapar Inc. | |
PDF 329 KB |
| 29 Jan 2019 | Strides to acquire 100% stake in Vensun Pharmaceuticals, Inc | |
PDF 326 KB |
| 29 Jan 2019 | SPSL Earnings Call Intimation | |
PDF 98 KB |
| 25 Jan 2019 | Strides to convert its 50:50 JV with Vivimed to 100% ownership | |
PDF 371 KB |
| 22 Jan 2019 | Announcement of Board Meeting | |
PDF 124 KB |
| Date | Title | Report |
|---|
| 31 Dec 2018 | Shareholding pattern for the quarter ended 31 December 2018 | |
PDF 4 MB |
| 24 Dec 2018 | USFDA approval for Polyethylene Glycol 3350 and Electrolytes for Oral Solution | |
PDF 185 KB |
| 19 Dec 2018 | Strides and Mylan to release General Claims Escrow on Agila transaction Strides to receive ~US$ 42 Mn immediately from General Claims Escrow | |
PDF 160 KB |
| 12 Dec 2018 | USFDA approval for Lidocaine Ointment | |
PDF 182 KB |
| 11 Dec 2018 | Strides Vivimed JV receives approval for Albendazole Tablets | |
PDF 158 KB |
| 22 Nov 2018 | Updates on Strides investments in Stelis Biopharma | |
PDF 147 KB |
| 09 Nov 2018 | Strides enters into a strategic partnership with SUDA Pharmaceuticals for the US market | |
PDF 172 KB |
| 02 Nov 2018 | Successful completion of US FDA inspection at its flagship facility in Bangalore | |
PDF 139 KB |
| 31 Oct 2018 | Press Release on CHC | |
PDF 1.12 MB |
| 31 Oct 2018 | Outcome of Board Meeting | |
PDF 3.78 MB |
| 25 Oct 2018 | Intimation on Board Meeting for quarter ended September 2018 | |
PDF 91.8 KB |
| 24 Oct 2018 | SPSL Earnings Call Intimation | |
PDF 147 KB |
| 20 Oct 2018 | US FDA Approval for Gabapentin Capsules | |
PDF 115 KB |
| 30 Sep 2018 | Shareholding Pattern for the Quarter ended 30 September 2018 | |
PDF 3.45 MB |
| 25 Sep 2018 | 27th Annual General Meeting Outcome - Voting Results & Scrutinizer Report | |
PDF 2.18 MB |
| 25 Sep 2018 | 27th Annual General Meeting Proceedings | |
PDF 605 KB |
| 20 Sep 2018 | ACCC announces clearance of the merger of Arrow Pharmaceuticals and Apotex Australia & NZ | |
PDF 867 KB |
| 18 Sep 2018 | Completion of USFDA inspection at Bangalore facility | |
PDF 529 KB |
| 05 Sep 2018 | USFDA Approval - Potassium Chloride Extended Release Tablets | |
PDF 776 KB |
| 31 Aug 2018 | Update on divestment of Strides Chemicals Private Limited, API asset at Ambernath | |
PDF 117 KB |
| 31 Aug 2018 | SE Intimation Notice of AGM and Book closure intimation | |
PDF 169 KB |
| 22 Aug 2018 | Strides receives acceptance from USFDA for two key ANDAs under newly introduced Competitive Generic Therapy | |
PDF 463 KB |
| 08 Aug 2018 | Grant of Options under Strides Shasun ESOP 2016 | |
PDF 70 KB |
| 08 Aug 2018 | Outcome of Board meeting | |
PDF 12 MB |
| 08 Aug 2018 | SPSL Earnings Call Intimation | |
PDF 104 KB |
| 31 Jul 2018 | Intimation of Board Meeting for quarter ended June 30, 2018 | |
PDF 122 KB |
| 20 Jul 2018 | Change in name of the Company to 'STRIDES PHARMA SCIENCE LIMITED' | |
PDF 126.3 KB |
| 02 Jul 2018 | Outcome of Postal Ballot | |
PDF 1.44 MB |
| 02 Jul 2018 | USFDA tentative approval for Milnacipran Hydrochloride Tablets | |
PDF 76 KB |
| 02 Jul 2018 | USFDA approval for Ibuprofen OTC Tablets | |
PDF 82 KB |
| 30 Jun 2018 | Shareholding Pattern | |
PDF 3.46 MB |
| 26 Jun 2018 | SE Intimation listing of shares issued by Solara | |
PDF 47 KB |
| 21 Jun 2018 | Strides Shasun’s Rectal Artesunate Product Receives WHO Prequalification | |
PDF 70 KB |
| 19 June 2018 | Strides Shasun receives USFDA approval for Ketoconazole Tablets USP, 200mg | |
PDF 67.7 KB |
| 11 Jun 2018 | Strides Shasun receives USFDA approval for Oseltamivir Phosphate Capsules | |
PDF 75 KB |
| 06 Jun 2018 | Strides Shasun SE Intimation on transfer of shares IEPF | |
PDF 277 KB |
| 29 May 2018 | Strides Shasun Intimation in Newspaper | |
PDF 512 KB |
| 29 May 2018 | Strides Shasun SE Intimation Clarification on Rumour | |
PDF 512 KB |
| 18 May 2018 | Strides Shasun Intimation of Postal Ballot and Evoting | |
PDF 1 MB |
| 18 May 2018 | Intimation to SE Merger of WOS | |
PDF 171 KB |
| 18 May 2018 | Intimation to SE Board Reconstitution | |
PDF 71 KB |
| 18 May 2018 | Strides Shasun Outcome of Board Meeting | |
PDF 6 MB |
| 18 May 2018 | Strides Shasun_Recommendation of final dividend | |
PDF 48 KB |
| 17 May 2018 | SSL Earnings Call Intimation | |
PDF 115 KB |
| 11 May 2018 | Announcement of Board Meeting to be held on May 18, 2018 | |
PDF 36 KB |
| 09 May 2018 | Strides & Apotex agree to merge their Australian businesses | |
PDF 80 KB |
| 02 May 2018 | USFDA approval for Cinacalcet Hydrochloride Tablets | |
PDF 74 KB |
| 24 Apr 2018 | Strides Shasun to divest its holding in remaining API asset at Ambernath | |
PDF 150 KB |
| 20 Apr 2018 | Intimation to SE on cost of acquisition | |
PDF 220 KB |
| 12 Apr 2018 | USFDA Approval for Cyproheptadine Hydrochloride Tablets | |
PDF 74 KB |
| 12 Apr 2018 | Intimation on allotment of shares by Solara Active | |
PDF 114 KB |
| 02 Apr 2018 | USFDA Approval For Ibuprofen Softgel OTC Capsules | |
PDF 72 KB |
| 31 Mar 2018 | Shareholding Pattern | |
PDF 4MB |
| 26 Mar 2018 | Strides Shasun Intimation on Effective Date and Record Date for allotment | |
PDF 120 KB |
| 23 Mar 2018 | SE Intimation - Receipt of NCLT Order relating to Demerger of Commodity API Business | |
PDF 111 KB |
| 14 Mar 2018 | USFDA Approval for Efavirenz Tablet | |
PDF 67 KB |
| 12 Mar 2018 | Intimation on appointment of Arun Kumar as KMP | |
PDF 55.6 KB |
| 12 Mar 2018 | Intimation on appointmentof Arun Kumar as Executive Chairman | |
PDF 50.7 KB |
| 07 Mar 2018 | Strides Shasun to launch Ranitidine 75mg OTC Tablets | |
PDF 70 KB |
| 26 Feb 2018 | Strides Shasun to launch Ranitidine OTC Tablets | |
PDF 119 KB |
| 09 Feb 2018 | Press Release – Q3 FY 18 | |
PDF 132 KB |
| 09 Feb 2018 | SSL_Consol Q3 FY 18 Financials | |
PDF 304 KB |
| 09 Feb 2018 | SSL_Standalone Q3 FY 18 Financials | |
PDF 124 KB |
| 09 Feb 2018 | Outcome of Board Meeting - Unaudited Financial Results for Dec 31, 2017 | |
PDF 2 MB |
| 09 Feb 2018 | Allotment of shares under ESOP 2015 | |
PDF 135 KB |
| 09 Feb 2018 | Newspaper Advertisement on hearing of petition | |
PDF 3 MB |
| 09 Feb 2018 | SSL Earnings Call Intimation | |
PDF 115 KB |
| 05 Feb 2018 | Clarification on Article appeared in Economic Times on February 5, 2018 titled “Blackstone, Strides, Nectar Lead Race for Orchid Pharma” | |
PDF 662 KB |
| 03 Feb 2018 | Intimation of Board Meeting for Q3 FY 17-18 | |
PDF 124 KB |
| 31 Jan 2018 | USFDA Approval for Nystatin and Triamcinolone Acetonide Ointment | |
PDF 72 KB |
| 31 Jan 2018 | USFDA Approval for Piroxicam capsules | |
PDF 65 KB |
| 29 Jan 2018 | USFDA Approval for Tenofovir Disoproxil Fumarate tablets | |
PDF 75 KB |
| 19 Jan 2018 | Update on ‘Strides Shasun acquires controlling stake in Trinity Pharma, South Africa’ | |
PDF 152 KB |
| Date | Title | Report |
|---|
| 31 Dec 2017 | Shareholding Pattern | |
PDF 906 KB |
| 28 Dec 2017 | Strides Shasun approval for composite scheme | |
PDF 2 MB |
| 20 Dec 2017 | Acquisition of Trinity Pharma | |
PDF 239 KB |
| 04 Dec 2017 | Update on ‘Divestment of India brand business to Eris Lifesciences’ | |
PDF 185 KB |
| 22 Nov 2017 | USFDA Approval for Acetazolamide Tablets | |
PDF 78 KB |
| 18 Nov 2017 | Strides Shasun divests India brand business to Eris Lifesciences | |
PDF 625 KB |
| 31 Oct 2017 | Press Release – Q2 FY 18 | |
PDF 242 KB |
| 31 Oct 2017 | SSL_Consol Q2 FY 18 Financials | |
PDF 307 KB |
| 31 Oct 2017 | SSL_Standalone Q2 FY 18 Financials | |
PDF 135 KB |
| 31 Oct 2017 | Strides Shasun Stock Exchange Intimation Post Meeting | |
PDF 1 MB |
| 31 Oct 2017 | SSL - Intimation to SE on Meger of WoS | |
PDF 239 KB |
| 31 Oct 2017 | Letter to SE_Allotment of shares under ESOP 2015 | |
PDF 44 KB |
| 30 Oct 2017 | SSL Earnings Call Intimation | |
PDF 45 KB |
| 27 Oct 2017 | Strides Shasun SE Intimation | |
PDF 42 KB |
| 25 Oct 2017 | Strides Shasun Announcement of Board Meeting | |
PDF 44 KB |
| 30 Sep 2017 | Shareholding Pattern | |
PDF 3 MB |
| 20 Sep 2017 | USFDA Approval for Omega-3-Acid Ethyl Esters capsules | |
PDF 55 KB |
| 15 Sep 2017 | Outcome of 26 th AGM - Disclosure under SEBI LODR | |
PDF 289 KB |
| 15 Sep 2017 | Voting Results and Scrutinizer Report of 26 th AGM | |
PDF 1.23 MB |
| 12 Sep 2017 | USFDA Approval for Potassium Citrate Extended-Release Tablets | |
PDF 60 KB |
| 01 Sep 2017 | EIR from US FDA on continued GMP status for flagship KRSG facility in Bangalore. | |
PDF 40 KB |
| 31 Aug 2017 | Arrow Pharmaceuticals acquires Amneal Pharmaceuticals in Australia | |
PDF 58 KB |
| 31 Aug 2017 | Intimation in newspaper advertisement on AGM notice | |
PDF 445 KB |
| 24 Aug 2017 | Notice of 26 th AGM | |
PDF 1.36 MB |
| 11 Aug 2017 | SSL_Consol Q1 FY 18 Financials | |
PDF 107 KB |
| 11 Aug 2017 | SSL Standalone Q1 FY 18 Financials. | |
PDF 92 KB |
| 11 Aug 2017 | Press Release – Q1 FY 18 | |
PDF 160 KB |
| 24 July 2017 | USFDA Approval for Cetirizine Softgel Capsules | |
PDF 56.3 KB |
| 03 July 2017 | USFDA Approval for Promethazine HCL Tablets | |
PDF 74.5 KB |
| 30 June 2017 | SSL Shareholding Pattern | |
PDF 720 KB |
| 30 June 2017 | CCI Approval for the Scheme | |
PDF 40.1 KB |
| 22 June 2017 | Update on transaction - Vivimed Labs | |
PDF 32.7 KB |
| 12 June 2017 | Clarification on Article appeared in online edition of Mint | |
PDF 34.3 KB |
| 12 June 2017 | Analyst investors meet schedule | |
PDF 60.4 KB |
| 12 June 2017 | USFDA Approval for Amantadine Hydrochloride Tablets | |
PDF 51.6 KB |
| 08 June 2017 | USFDA Approval for Amantadine Hydrochloride Capsules | |
PDF 49.7 KB |
| 07 June 2017 | Strides Shasun SE Intimation Update on Credit Rating | |
PDF 26.7 KB |
| 01 June 2017 | USFDA Approval For Ibuprofen Tablets | |
PDF 54.6 KB |
| 29 May 2017 | Completion of USFDA inspection at Bangalore Facility | |
PDF 31.7 KB |
| 26 May 2017 | Strides Shasun Declaration Pursuant to Reg 33 of SEBI LODR | |
PDF 47.5 KB |
| 24 May 2017 | USFDA Approval for Memantine Tablets | |
PDF 50.1 KB |
| 18 May 2017 | Auditors appointment | |
PDF 82.1 KB |
| 18 May 2017 | SE Intimation Grant of Options | |
PDF 40.4 KB |
| 18 May 2017 | Strides Shasun Board Reconstitution | |
PDF 191 KB |
| 18 May 2017 | Strides Shasun Vivimed JV 18 May 2017 | |
PDF 147 KB |
| 18 May 2017 | SSL - Consol FY 17 Financials | |
PDF 218 KB |
| 18 May 2017 | SSL - Standalone FY 17 Financials | |
PDF 153 KB |
| 18 May 2017 | Press Release – FY 17 | |
PDF 208 KB |
| 17 May 2017 | SSL Earnings Call Intimation | |
PDF 47.1 KB |
| 11 May 2017 | Strides Shasun announcement of Board Meeting | |
PDF 42.8 KB |
| 05 May 2017 | Successful completion of third consecutive US FDA inspection with ‘Zero 483 Status’ over the last month 5 May 2017 | |
PDF 66.8 KB |
| 04 May 2017 | Strides Shasun SE Intimation | |
PDF 40.2 KB |
| 28 Apr 2017 | Strides Shasun SE Announcement | |
PDF 267 KB |
| 24 Apr 2017 | Strides Shasun SE Intimation | |
PDF 39.1 KB |
| 06 Apr 2017 | Strides Shasun SE Intimation | |
PDF 38.9 KB |
| 31 Mar 2017 | Shareholding pattern 31 st March 2017 | |
PDF 804 KB |
| 27 Mar 2017 | Strides Shasun SE Claratification | |
PDF 44.4 KB |
| 22 Mar 2017 | Scrutinizer Report_Capping of Strides’ investment in Stelis | |
PDF 545 KB |
| 20 Mar 17 | Outcome of Board Meeting De-merger of Commodity API biz | |
PDF 184 KB |
| 28 Feb 17 | Postal ballot newspaper advertisment | |
PDF 886 KB |
| 21 Feb 17 | Intimation of Postal Ballot & E-Voting | |
PDF 892 KB |
| 03 Feb 17 | SSL Press Release Corporate Actions | |
PDF 95.2 KB |
| 03 Feb 17 | SSL Standalone Q3 FY17 Financials | |
PDF 56.4 KB |
| 03 Feb 17 | SSL Consol Q3 FY17 Financials | |
PDF 90.8 KB |
| 03 Feb 17 | Press Release Q3 FY 2017 | |
PDF 191 KB |
| 03 Feb 17 | Intimation of change in Company Secretary | |
PDF 39.4 KB |
| 02 Feb 17 | Fingolimod Capsules-Tentatively Approved | |
PDF 53.3 KB |
| 02 Feb 17 | Earnings Call Intimation | |
PDF 40.4 KB |
| 01 Feb 17 | Clarification on TOI report | |
PDF 44.3 KB |
| 25 Jan 17 | Strides Shasun announcement of Board Meeting | |
PDF 41.5 KB |
| Date | Title | Report |
|---|
| 31 Dec 16 | SSL Shareholding Pattern | |
PDF 732 KB |
| 09 Dec 16 | Strides Shasun Perrigo Press Release | |
PDF 57 KB |
| 25 Nov 16 | Strides Shasun Press Release | |
PDF 65 KB |
| 03 Nov 16 | Stock Exchange Intimation – Mylan settlement | |
PDF 90 KB |
| 28 Oct 16 | Intimation of designation of Group CEO as Key Managerial Personnel | |
PDF 36 KB |
| 28 Oct 16 | Intimation on Allotment of Equity Shares to Employees on exercise of ESO | |
PDF 37 KB |
| 28 Oct 16 | Intimation on Dividend Policy | |
PDF 35 KB |
| 28 Oct 16 | Intimation on Grant of Options under Strides Arcolab ESOP 2015 | |
PDF 37 KB |
| 28 Oct 16 | SSL_Standalone Q2 FY17 Financials | |
PDF 115 KB |
| 28 Oct 16 | SSL_Consol Q2 FY17 Financials | |
PDF 93 KB |
| 28 Oct 16 | Press Release - Q2 FY17 | |
PDF 189 KB |
| 21 Oct 16 | Strides Shasun Announcement of Board Meeting | |
PDF 39 KB |
| 30 Sep 16 | SSL Shareholding Pattern | |
PDF 672 KB |
| 25 Aug 16 | Strides Shasun receives USFDA Approval for Polyethylene Glycol 3350, Powder for Solution (OTC) | |
PDF 61 KB |
| 24 Aug 16 | Strides Shasun receives USFDA Approval for Ranitidine Tablets | |
PDF 55 KB |
| 17 Aug 16 | Generic Partners Holdings, Australia – transaction achieved closure | |
PDF 122 KB |
| 17 Aug 16 | Press Release - Q1 FY17 | |
PDF 170 KB |
| 29 Jul 16 | Report of Scrutinizer AGM | |
PDF 210 KB |
| 30 Jun 16 | Shareholding pattern | |
PDF 909 KB |
| 30 Jun 16 | Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore | |
PDF 54 KB |
| 28 Jun 16 | Scrutinizer’s Report - Divestment of CRAMS Business | |
PDF 495 KB |
| 07 Jun 16 | EIR from US FDA for Oral Dosage Facility, Bangalore | |
PDF 28 KB |
| 07 Jun 16 | Universal Corporation, Kenya – transaction achieved closure | |
PDF 24 KB |
| 01 Jun 16 | Strides Shasun receives USFDA Tentative Approval for Roflumilast Tablets | |
PDF 53 KB |
| 27 May 16 | Strides Shasun receives USFDA Approval for Metronidazole Tablets | |
PDF 55 KB |
| 26 May 16 | Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet | |
PDF 52 KB |
| 16 May 16 | Press Release - Q4 FY16 and FY16 | |
PDF 118 KB |
| 16 May 16 | Results presentation - Q4 FY16 and FY16 | |
PDF 1.87 MB |
| 16 May 16 | SE Intimation - Pharmacy Alliance | |
PDF 252 KB |
| 16 May 16 | SE Intimation - Divestment of Shasun Pharma Solutions Ltd, UK (CRAMS API Biz.) | |
PDF 284 KB |
| 10 May 16 | Strides Shasun Announcement of Board Meeting | |
PDF 29 KB |
| 27 Apr 16 | Update on “Acquisition of controlling stake in Universal Corporation, Kenya Receipt of approval from Competition Authority of Kenya" | |
PDF 30 KB |
| 26 Apr 16 | Strides Shasun SE Claratification | |
PDF 29 KB |
| 22 Apr 16 | Outcome of Postal Ballot - Approval of ESOP 2016 | |
PDF 951 KB |
| 06 Apr 16 | SE Clarification - Economic Times article | |
PDF 29 KB |
| 04 Apr 16 | Update on Moberg Pharma – transaction achieved closure | |
PDF 26 KB |
| 31 Mar 16 | Strides Shareholding Pattern | |
PDF 698 KB |
| 21 Mar 16 | SE Intimation on Postal Ballot & Evoting | |
PDF 1.30 MB |
| 21 Mar 16 | SE Intimation on Postal Ballot & Evoting | |
PDF 1.30 MB |
| 07 Mar 16 | Allotment of Equity Shares to Employees on exercise of ESOPs | |
PDF 29 KB |
| 07 Mar 16 | Strides Shasun to acquire 3 brands from Moberg Pharma for USD 10 Million | |
PDF 70 KB |
| 23 Feb 16 | Update on GMS Holdings strategic investment in Stelis Biopharma | |
PDF 28 KB |
| 08 Feb 16 | Acquisition of Generic Partners Holdings | |
PDF 72 KB |
| 08 Feb 16 | Acquisition of Universal Corporation, Kenya | |
PDF 60 KB |
| 08 Feb 16 | Press Release Q3 FY16 8 Feb 2016 | |
PDF 175 KB |
| 08 Feb 16 | SSL Consol Q3 FY 2016 Financials | |
PDF 87 KB |
| 08 Feb 16 | SSL_Standalone Q3 FY 2016 Financials | |
PDF 67 KB |
| 08 Feb 16 | Appointment of Mr. Shashank Sinha as CEO | |
PDF 36 KB |
| 03 Feb 16 | Acquisition of seven brands from Johnson & Johnson - transaction achieved closure | |
PDF 34 KB |
| 01 Feb 16 | Acquisition of CNS divisions of erstwhile Ranbaxy - transaction achieved closure | |
PDF 52 KB |
| 27 Jan 16 | CCI approval_Johnson & Johnson | |
PDF 25 KB |
| 22 Jan 16 | Update on “Acquisition of CNS division of erstwhile Ranbaxy” | |
PDF 143 KB |
| 20 Jan 16 | Shareholding Pattern - 31 December 2015 | |
PDF 808 KB |
| 19 Jan 16 | Clarification on Business Standard article | |
PDF 35 KB |
| Date | Title | Report |
|---|
| 21 Dec 15 | Strides Shasun receives approval from Drug Controller General of India for generic version of Sofosbuvir | |
PDF 70.4 KB |
| 17 Dec 15 | Strides Shasun Letter to StockExchange Dec 17 2015 | |
PDF 35.3 KB |
| 14 Dec 15 | Strides Shasun EGM-Coverpage | |
PDF 28.7 KB |
| 11 Dec 15 | Strides Arcolab letter | |
PDF 474 KB |
| 12 Dec 15 | Annexure 1 Outcome & Voting Results of EGM as per Reg 44(3) | |
PDF 1.23 MB |
| 12 Dec 15 | Annexure 2 Scrutinizer Combined Report-On poll and e-voting | |
PDF 130 KB |
| 16 Dec 15 | Strides Shasun Response to Biz Standard Article-16 Dec 2015 | |
PDF 21.7 KB |
| 15 Dec 15 | Strides Response to NSE 15 Dec 2015 | |
PDF 75.3 KB |
| 15 Dec 15 | Strides Response to BSE 15 Dec 2015 | |
PDF 62.5 B |
| 23 Nov 15 | strides Shasun Stock Exchange Intimation | |
PDF 45 KB |
| 20 Nov 15 | Strides Shasun - Intimation of EGM | |
PDF 1.80 MB |
| 20 Nov 15 | Strides Shasun - Allotment | |
PDF 55 KB |
| 19 Nov 15 | Strides Arcolab_Name change letter | |
PDF 51 KB |
| 05 Nov 15 | Strides Arcolab_Intimation to Stock Exchange | |
PDF 56 KB |
| 29 Oct 15 | FIPB Approval Intimation to Stock Exchange | |
PDF 100 KB |
| 27 Oct 15 | Press Release Q2 FY16 INR | |
PDF 154 KB |
| 27 Oct 15 | Consol SEBI Q2 2015-16 | |
PDF 91 KB |
| 27 Oct 15 | Standalone SEBI Q2 2015-16 | |
PDF 74 KB |
| 06 Oct 15 | Intimation of Postal Ballot | |
PDF 1.36 MB |
| 28 Sept 15 | Intimation to SE_Fund Raising | |
PDF 47 KB |
| 19 Sept 15 | Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy | |
PDF 92 KB |
| 16 Sept 15 | Update on Scheme of Amalgamation of Shasun and Strides | |
PDF 48 KB |
| 31 Aug 15 | Update on ‘Acquisition of a generic pharmaceutical business in Australia | |
PDF 44 KB |
| 31 July 15 | Strides Arcolab receives ANDA approval from US FDA for Benzonatate Softgel Capsules | |
PDF 124 KB |
| 30 July 15 | SAL - Consolidated financial statements | |
PDF 78 KB |
| 30 July 15 | SEBI Standalone | |
PDF 78 KB |
| 30 July 15 | Strides Arcolab announces Q1 FY16 Results | |
PDF 492 KB |
| 10 July 15 | Strides arcolab scrutinizer's report | |
PDF 560 KB |
| 10 July 15 | Strides arcolab combined result clause 35 format | |
PDF 120 KB |
| 10 July 15 | Strides arcolab outcome of postal ballot cover note | |
PDF 138 KB |
| 19 June 15 | Strides Intimation | |
PDF 53 KB |
| 17 June 15 | Strides Arcolab Update on Scheme of Amalgamation | |
PDF 50 KB |
| 22 May 15 | Strides Arcolab announces Q4 FY15 and FY15 Results | |
PDF 535 KB |
| 21 May 15 | Strides inks agreements to acquire a generic pharmaceutical business in
Australia and
related assets from Aspen for approximately A$380 million Acquisition to be EPS accretive immediately |
|
PDF 82.2 KB |
| 15 May 15 | Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine Tablets | |
PDF 63.8 KB |
| 15 April 15 | Strides Arcolab receives ANDA approval from US FDA for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution. | |
PDF 79 KB |
| 27 Feb 15 | Launch of generic drug Sofosbuvir in India under the brand name 'Virso' | |
PDF 56.8 KB |
| 02 Feb 15 | Statement Of Standalone Unaudited Results For The Nine Months Ended December 31, 2014. | |
PDF 67 KB |
| 02 Feb 15 | Strides Arcolab reports Q3 FY 2014-15 Results Pharma Revenues at INR 3,261 Mn with an EBITDA of INR 664 Mn EBITDA Margin at 20%. | |
PDF 127 KB |
| 20 Jan 15 | Strides Arcolab signs Agreement with Gilead Sciences to Manufacture and Distribute Tenofovir Alafenamide (TAF) based HIV treatments in 112 Developing Countries. | |
PDF 57 KB |
| 13 Jan 15 | Singapores Economic Development Board grants International Headquarter Status to Strides Pharma Global Pte. Ltd. Singapore. | |
PDF 82 KB |
| Date | Title | Report |
|---|
| 16 Dec 14 | Strides Arcolab receives US FDA approval for Calcitriol Softgel Capsules. | |
PDF 65 KB |
| 03 Dec 14 | Stelis Biopharma Begins Construction of Multi-Product Biologics Facility At Bioxcell Biotechnology Park, Johor, Malaysia. | |
PDF 210 KB |
| 27 Nov 14 | Strides Arcolab Press Release MMV announces collaborations with Cipla and Strides. | |
PDF 72 KB |
| 20 Nov 14 | Appointment of Mr. Abhaya Kumar | |
PDF 43 KB |
| 07 Nov 14 | Strides Arcolab reports Robust Q2 FY 2014-15 Results. | |
PDF 126 KB |
| 01 Oct 14 | Strides Arcolab clarifies on the Import Alert published on the US FDA website regarding its subsidiary Beltapharm SpA, Italy. | |
PDF 58 KB |
| 29 Sept 14 | Strides Arcolab announces strategic Investor for its greenfield Biotech project. | |
PDF 87 KB |
| 29 Sept 14 | Strides Arcolab and Shasun Pharmaceuticals combine to accelerate strategy and growth. | |
PDF 142 KB |
| 15 Sept 14 | Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. | |
PDF 88 KB |
| 26 Aug 14 | Strides Arcolab receives US FDA approval for Buspirone Tablets. | |
PDF 92 KB |
| 25 Jul 14 | Strides Arcolab announces Q1 FY 2014-15 Results. | |
PDF 73 KB |
| 23 Jul 14 | Strides Arcolab receives USFDA approval for Tacrolimus Capsules. | |
PDF 92 KB |
| 21 Jul 14 | Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. | |
PDF 82 KB |
| 16 Jul 14 | Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. | |
PDF 210 KB |
| 25 Jun 14 | Strides Arcolab receives US FDA approval for Imiquimod Cream. | |
PDF 77 KB |
| 06 Jun 14 | Strides Arcolab receives US FDA approval for Methoxsalen Softgel Capsules. | |
PDF 78 KB |
| 23 May 14 | Strides financial results for the Quarter ending March 31, 2014 and Financial Year ending March 31, 2014. | |
PDF 81 KB |
| 25 Apr 14 | Strides reports continued US FDA approval Status for Oral Dosage Facility. | |
PDF 76 KB |
| Date | Title | Report |
|---|
| 10 Dec 13 | Update on Agila Transaction. | |
PDF 107 KB |
| 5 Dec 13 | Strides Arcolab completes sale of Agila Specialties division to Mylan. | |
PDF 113 KB |
| 14 Nov 13 | Strides Arcolab announces Q3'13 Results. | |
PDF 84 KB |
| 23 Oct 13 | Stelis Biopharma signs a Research Collaboration Agreement with Bio-Scaffold International Pte Ltd to develop scaffolds loaded with BMP and stem cells for various medical applications. | |
PDF 124 KB |
| 18 Sep 13 | Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. | |
PDF 75 KB |
| 1 Aug 13 | Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablets. | |
PDF 76 KB |
| 25 Jul 13 | Global Pharma business in line with Guidance. | |
PDF 81 KB |
| 25 Jun 13 | Strides announces WHO pre-qualification for Artemether+Lumifantrine (AL). | |
PDF 68 KB |
| 25 Apr 13 | Strides reports strong quarterly performance - Standalone Financial Highlights. | |
PDF 80 KB |
| 16 Apr 13 | Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market. | |
PDF 85 KB |
| 19 Mar 13 | Malaysian Bio-Xcell SDN BHD seals a deal exceeding US$35M (~RM107M) with AGILA Biotech SDN BHD during Biopharma Asia 2013. | |
PDF 98 KB |
| 06 Mar 13 | Agila Receives Us FDA approval for Zoledronic Acid Injection. | |
PDF 86 KB |
| 28 Feb 13 | Strides Arcolab to Sell AGILA Specialties Division to Mylan INC. For An Aggregate Sum of US$1,600 Million in Cash and Potential Additional Consideration Of Up To US$250 Million. | |
PDF 355 KB |
| 28 Feb 13 | Strides reports Continued Strong Operational Performance. | |
PDF 147 KB |
| Date | Title | Report |
|---|
| 05 Dec 12 | Strides Arcolab and Lilly Enter Strategic Partnership to Deliver High-Quality, Branded Generic Cancer Medicines for Emerging Markets. | |
PDF 90 KB |
| 19 Oct 12 | Strides reports Continued Strong Operational Performance in Q3'12. | |
PDF 93 KB |
| 18 Oct 12 | Strides Arcolab Receives 2 More Approvals For Oncology Products from USFDA. | |
PDF 84 KB |
| 13 Sep 12 | Strides Arcolab Announces US FDA Approval of Its Polish Sterile Injectable Facility. | |
PDF 81 KB |
| 03 Sep 12 | Strides Arcolab Receives US FDA Approval For Vinorelbine Injection. | |
PDF 86 KB |
| 29 Aug 12 | Strides Arcolab Receives US FDA Approval For Topotecan Injection. | |
PDF 86 KB |
| 8 Aug 12 | Strides Arcolab Receives Us FDA Approval For Oxaliplatin Injection. | |
PDF 87 KB |
| 6 Aug 12 | Strides collaborates with Gilead Sciences. | |
PDF 67 KB |
| 27 Jul 12 | Strides reports Strong Operational Performance in Q2'12. | |
PDF 133 KB |
| 24 Jul 12 | Proparco Investment in Strides' African Arm. | |
PDF 67 KB |
| 20 Jul 12 | Strides Arcolab Receives US FDA Approval For Fluorouracil Injection. | |
PDF 77 KB |
| 27 Jun 12 | Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. | |
PDF 100 KB |
| 11 Jul 12 | Agila Announces Entry Into Canadian Injectable Market. | |
PDF 79 KB |
| 27 Jun 12 | Strides redeems FCCBs due 2012 Net Debt / Equity at 0.75. | |
PDF 100 KB |
| 10 May 12 | Strides Arcolab Receives US FDA Approval for Acetazolamide Injection, USP. | |
PDF 89 KB |
| 26 Apr 12 | Strides delivers Robust Q1'12 Performance. | |
PDF 133 KB |
| 26 Apr 12 | Strides acquires US FDA approved Sterile Formulations facility. | |
PDF 76 KB |
| 19 Apr 12 | Strides Arcolab Receives US FDA Approval Forcisplatin Injection. | |
PDF 85 KB |
| 11 Apr 12 | Strides Arcolab Receives US FDA Nod For Vancomycin Oral Capsules. | |
PDF 77 KB |
| 3 Apr 12 | Strides Arcolab Announces Health Canada Approval for Tobramycin Injection. | |
PDF 77 KB |
| 30 Mar 12 | Strides Arcolab Receives US FDA Approval For Methotrexate Injection. | |
PDF 84 KB |
| 27 Feb 12 | Audited Financial Results Year Ended December 31, 2011. | |
PDF 152 KB |
| 24 Feb 12 | Strides Arcolab Announces Us FDA Approval For Its 'Brazilian Sterile Penems Facility'. | |
PDF 93.2 KB |
| 24 Jan 12 | Sale of generic pharmaceutical operations in Australia and Southeast Asia for AU$375 million - Analyst Presentation | |
PDF 1.33 MB |
| 24 Jan 12 | Strides Arcolab Sells Its Generic Pharmaceutical Operations In Australia and Southeast Asia to Watson Pharmaceuticals for Au$ 375 Million. | |
PDF 79 KB |
| Date | Title | Report |
|---|
| 22 Dec 11 | Strides Press Release Sterile Plant Approval and Fludarabine Approval. | |
PDF 104 KB |
| 15 Dec 11 | Strides Press Release Cytarabine Approval. | |
PDF 99 KB |
| 24 Nov 11 | Approval Momentum for Oncology Products Continues With Two More USFDA Approvals. | |
PDF 106 KB |
| 11 Nov 11 | Strides Arcolab receives US FDA approval for Carboplatin Injection. | |
PDF 178 KB |
| 02 Nov 11 | Strides Arcolab Receives US FDA Approval for Doxorubicin Injection. | |
PDF 87 KB |
| 24 Oct 11 | Strides Results Pack Financials for Q3 '11. | |
PDF 974 KB |
| 24 Oct 11 | Strides delivers Superior Q3 '2011 Financials Ups Full Year Guidance | |
PDF 125 KB |
| 20 Oct 11 | Strides Arcolab Receives US FDA Approval For Bupivacaine Hydrochloride Injection, USP | |
PDF 77 KB |
| 10 Oct 11 | Strides Arcolab Receives US FDA Approval for Cladribine Injection | |
PDF 77 KB |
| 03 Oct 11 | Strides Arcolab Receives US FDA Approval For Clindamycin Injection, USP | |
PDF 74 KB |
| 30 Sep 11 | Strides Oncology Approvals Gain Momentum With Two More USFDA Approvals | |
PDF 88 KB |
| 15 Sep 11 | Strides Announces European Approval For Oxaliplatin Injection | |
PDF 90 KB |
| 14 Sep 11 | Strides continued US FDA Approval Status For Oral Dosage Facility | |
PDF 66 KB |
| 28 July 11 | Strides Arcolab Announces US FDA Approval For Acarbose Tablets | |
PDF 106 KB |
| 26 July 11 | Strides Arcolab Announces US FDA Approval For Gemcitabine For Injection USP | |
PDF 77 KB |
| 1 July 11 | Strides Announces European Approval For Its Oral Dosage Facility In Its Oncology Complex | |
PDF 50 KB |
| 1 July 11 | Strides Arcolab Receives US FDA Approval For Polymyxin Injection | |
PDF 50 KB |
| 29 Jun 11 | Strides Arcolab Joins The Malaysian BIO-XCELL Ecosystem | |
PDF 50 KB |
| 21 Jun 11 | Strides Arcolab Receives US ADA Approval For Levofloxacin Injection | |
PDF 50 KB |
| 5 May 11 | Strides Arcolab Receives US FDA Approval For Midazolam Injection Multi-Dose Vials | |
PDF 50 KB |
| 2 May 11 | Strides announces US FDA approval for its Oncology facility in Bangalore | |
PDF 50 KB |
| 25 Apr 11 | Results Pack Financials for Q1 2011 | |
PDF 50 KB |
| 25 Apr 11 | Strides Announces Q1 ‘2011 Financial Results | |
PDF 50 KB |
| 18 Apr 11 | Strides Arcolab Announces US FDA Approval For Its ‘New Sterile Injectable Facility | |
PDF 50 KB |
| 13 Apr 11 | Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility | |
PDF 50 KB |
| 4 Mar 11 | Strides Announces First European Approval For Oncology Product | |
PDF 50 KB |
| 1 Mar 11 | Strides arcolab receives US FDA nod to commercialize first sterile product from new facility | |
PDF 50 KB |
| 24 Feb 11 | Results Pack Financials for the year 2010 | |
PDF 50 KB |
| 24 Feb 11 | Press Release | |
PDF 50 KB |
| 20 Jan 11 | AGILA Signs Agreement with Biochimico To Set Up A Joint Venture Company In Brazil. | |
PDF 50 KB |
| 18 Jan 11 | Strides Arcolab announces US FDA Approval for additional Adenosine Injection USP | |
PDF 50 KB |
| Date | Title | Report |
|---|
| 10 Dec 10 | Strides Arcolab Announces US FDA Approval for Lidocaine Hydrochloride Injection. | |
PDF 50 KB |
| 09 Dec 10 | Strides acquires controlling stake in Inbiopro. | |
PDF 50 KB |
| 01 Dec 10 | Strides Arcolab Announces US FDA Approval Of Midazolam Hydrochloride Injection. | |
PDF 50 KB |
| 25 Nov 10 | Strides Specialties Rebranded As Agila Specialties. | |
PDF 50 KB |
| 29 Oct 10 | Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine under PEPFAR scheme. | |
DF 50 KB |
| 27 Oct 10 | Strong Performance Across Business Divisions Steers 35% Growth In Revenue For Strides. | |
PDF 50 KB |
| 26 Oct 10 | Strides' Generic Oseltamivir Receives WHO Prequalification for treatment of H1N1. | |
PDF 50 KB |
| 04 Oct 10 | Strides Arcolab Records 50th Anda Approval 2 More Anda Approvals Received. | |
PDF 50 KB |
| 04 Aug 10 | Strides Arcolab announces US FDA approval for Ergocalciferol Capsules 1.25mg first approval for a Soft Gelatine Product. | |
PDF 50 KB |
| 03 Aug 10 | Strides' Sterile Carbapenems Facility In Campos, Brazil receives MHRA Approval. | |
PDF 50 KB |
| 30 Jul 10 | Strides Arcolab Announces US FDA Approval of Sumatriptan Succinate Injection. | |
PDF 50 KB |
| 30 Jul 10 | Strides Arcolab Announces US FDA Approval of Rocuronium Bromide Injection. | |
PDF 50 KB |
| 27 Jul 10 | Strides today announced Q2-10 results. | |
DF 50 KB |
| 13 Jul 10 | Strides Annual Report 2009 Wins LACP Platinum Award. | |
PDF 50 KB |
| 18 May 10 | Strides Arcolab Receives ANDA approval from US FDA for Abacavir Sulfate Tablets, 300mg under PEPFAR Scheme. | |
PDF 50 KB |
| 14 May 10 | Strides and Pfizer Strengthen Partnership. | |
PDF 50 KB |
| 13 May 10 | Strides Arcolab announces US FDA Approval of Vecuronium Bromide for Injection. | |
PDF 50 KB |
| 12 May 10 | Strides Arcolab announces US FDA Approval Of Bacitracin For Injection, USP. | |
PDF 50 KB |
| 11 May 10 | Manish Gupta to lead Pharma Business at Strides Arcolab. | |
PDF 50 KB |
| 22 Apr 10 | Strides Arcolab Announces US FDA Tentative Approval Of Additional Adenosine Injection. | |
PDF 50 KB |
| 22 Apr 10 | Strides today announced Q1'10 financials. | |
PDF 50 KB |
| 21 Apr 10 | Strides Arcolab Announces US FDA Approval For Metoprolol Tartrate Injection. | |
PDF 50 KB |
| 20 Apr 10 | Strides redeems USD 34 Million FCCBs due 2010. | |
PDF 50 KB |
| 19 Apr 10 | Strides Arcolab Announces US FDA Approval For Mesna Injection. | |
PDF 50 KB |
| 14 Apr 10 | Strides Arcolab Announces US FDA Approval For Granisetron Hydrochloride Injection. | |
PDF 50 KB |
| 18 Mar 10 | Strides revises guidance upwards for FY 2010. | |
PDF 50 KB |
| 18 Mar 10 | Strides and Aspen restructure Oncology arrangements. | |
PDF 50 KB |
| 04 Mar 10 | Strides to acquire Campos facility in Brazil from Aspen. | |
PDF 50 KB |
| 24 Feb 10 | Results Pack Financials for the year 2009. | |
PDF 50 KB |
| 24 Feb 10 | Audited Financial Results for the Year ended 31 December 2009. | |
PDF 50 KB |
| 09 Feb 10 | Strides Arcolab announces US FDA approval for Labetalol Hydrochloride injection, USP – total Approvals in sterile space at 18. | |
PDF 50 KB |
| 20 Jan 10 | Strides Arcolab appoints Venkat Iyer To Board of Directors. | |
PDF 54 KB |
| 6 Jan 10 | Pfizer and Strides Arcolab to Collaborate on Generic Products. | |
PDF 74 KB |
- Press Kit
- Download
